ChloraSolv is regulatory approved for diabetic foot ulcers in New Zealand
RLS Global has received regulatory approval for ChloraSolv for treatment of diabetic foot ulcers in New Zealand. With this approval, RLS has established a first market presence in Oceania. The next step will be to broaden the indication in this market.
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q2, 2021
APRIL 1[st] – JUNE 3O[th] · Net sales amounted to TSEK 244 (TSEK 739) · Earnings before interest and taxes (EBIT) amounted to MSEK 8,5 (MSEK -5,6) · Other income TSEK 15 429 (TSEK 281) · Earning per share before dilution at SEK SEK 0,13 (SEK-0,09) · Cash flow from operating activities amounted to MSEK…
Read moreRLS Global AB and ConvaTec Ltd sign agreement on global commercial rights for ChloraSolv, an innovative wound debrider indicated for hard-to-heal wounds
RLS Global, a medical healthcare company based in Sweden and ConvaTec, one of the world’s leading companies in advanced wound care, have entered a global collaboration to commercialize ChloraSolv. ChloraSolv is a ground-breaking gentle debrider, which is already currently sold in some European countries. ChloraSolv will be included in ConvaTec’s Wound Hygiene[TM] Protocol of care…
Read moreRLS Global clinical study, ChloraSolv01, published in the Journal of Wound Care
RLS Global is pleased to announce that the outcome of the completed clinical study ChloraSolv01 is published today in the Journal of Wound Care Vol 30, No 6, June 2021. Data from this clinical study show that a treatment regimen based on ChloraSolv could represent a valuable treatment option for patients suffering from hard-to-heal wounds.
Read moreChloraSolv is regulatory approved in Kuwait for diabetic foot ulcers
RLS Global AB has received regulatory approval for ChloraSolv regarding the treatment of diabetic foot ulcers in Kuwait. With this approval, RLS has established the first market presence in the Middle East, which is an important region for RLS. The prevalence of diabetes in the Middle East is very high and is expected to increase…
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2021
JAN 1[st] – MARCH 31[st] · Net sales amounted to KSEK 50 (KSEK 374) · Earnings before interest and taxes (EBIT) amounted to MSEK -6,3 (MSEK -3,9) · Earning per share before dilution at SEK -0,09 (SEK-0,06) · Cash flow from operating activities amounted to MSEK -5,8 (MSEK-4,2) · Liquid assets at the end of…
Read moreChloraSolv is approved for leg ulcers – doubles the potential market size in Europe
RLS Global, whose ambition is to be a leading research-driven platform company for wounds, has received regulatory approval that ChloraSolv can also be used for leg ulcers. This increases the potential market size by 100 percent. ChloraSolv has been approved for diabetic foot ulcers since 2019, where now leg ulcers also are included.
Read moreRLS GLOBAL AB (publ) YEAR-END REPORT 2020
OCTOBER 1[st]–DECEMBER 31[st] · Net sales amounted to KSEK 139 (KSEK 54) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,2 (MSEK -8,9) · Earning per share before dilution at SEK -0,11 (SEK -0,15) · Cash flow from operating activities amounted to MSEK -7,0 (MSEK -5,7) · Liquid assets at the end of…
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q3, 2020
JULY 1[st] - SEPTEMBER 30[th] · Net sales amounted to KSEK 793 (KSEK 245) · Earnings before interest and taxes (EBIT) amounted to MSEK -5,6 (MSEK -6,2) · Earning per share before dilution at SEK -0,08 (SEK-0,11) · Cash flow from operating activities amounted to MSEK -4,2 (MSEK-7,4) · Liquid assets at the end of…
Read moreRLS Global presents positive results from the ChloraSolv01 study at the leading European Wound Management Conference, EWMA 2020
RLS Global is pleased to announce that an abstract has been reviewed by the EWMA Scientific Committee and accepted for Oral Presentation at the EWMA 2020 Virtual Conference. The abstract “ID no. 927” will be presented by Senior consultant, Associate professor Jan Apelqvist, Skåne University Hospital, Sweden.
Read moreChloraSolv is awarded by Region Skåne
RLS Global is pleased to inform about the acceptance of ChloraSolv by Region Skåne. ChloraSolv is available as of today, September 29[th]. This is the result of positive clinical evaluations from both acute- and primary care and it is an important milestone for RLS as Region Skåne is one of the largest regions in Sweden…
Read moreRLS Global presents data about ChloraSolv and its rapid response and high efficacy on biofilm
At the EWMA (European Wound Management Association) Conference in November, RLS will present data where our technology has been evaluated in an ex-vivo wound model with very exciting results on biofilm. The evaluation was carried out together with RISE, Research Institute of Sweden.
Read moreRLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2020
APRIL 1[st] - JUNE 30[th] · Net sales amounted to TSEK 739 (TSEK 464) · Earnings before interest and taxes (EBIT) amounted to MSEK -5,6 (MSEK -5,8) · Earnings per share before dilution at SEK -0,09 (SEK-0,02) · Cash flow from operating activities amounted to MSEK -5,5 (MSEK-6,3) · Liquid assets at the end of…
Read moreRLS clinical trial - ChloraSolv01 – is completed and the result is to be analyzed
RLS Global is pleased to announce that the database for ChloraSolv01 is closed and RLS has received the first statistical report and results. ChloraSolv01 is a pilot study in which the patient with chronic ulcers on the lower leg or foot is treated with ChloraSolv for five weeks. The study endpoints include for example the…
Read moreRLS Global AB has signed an agreement with Region Stockholm and Gotland for ChloraSolv®
RLS Global AB is pleased to inform that ChloraSolv is awarded on the current tender agreement in Region Stockholm and Gotland. The agreement is effective August 15[th], 2020. The clinical evaluation has been very positive and ChloraSolv is now available to all healthcare providers in the region such as inpatient- and outpatient care, primary care,…
Read moreIncreased interest in CariSolv due to the Corona pandemic
One consequence of the Corona pandemic is that the dental industry is facing a major shift in terms of caries treatment. Traditional treatment of caries attacks is done with drilling and repair. In connection with drilling in the tooth, aerosol is formed which radically increases the spread of infection during treatment. The dental industry is…
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2020
JANUARY 1[st] - MARCH 31[st] · Net sales amounted to TSEK 374 (260 TSEK) · The operating loss for the period was MSEK -3.9 (-5.7 MSEK) · Earnings per share after dilution at SEK -0.06 (-0.04) · Cash flow from operating activities amounted to MSEK -4.2 (-5.5 MSEK) · Equity ratio was 92 percent (84…
Read moreRLS Global (publ) change Certified Adviser to Redeye AB
RLS Global AB announces today that the company will change Certified Adviser from Erik Penser Bank to Redeye AB. The transition will take place as of April 1[st], 2020. The background is that RLS will gather all advice with Redeye AB.
Read moreChloraSolv is awarded on wound care tender in Region Kalmar Country Council and its municipalities
During the fall of 2019, RLS Global has worked intensively on the Swedish market with the aim to establish ChloraSolv as a product in the Swedish regions. In parallel, RLS has worked in close collaboration with OneMed to penetrate the market (municipalities and regions) where OneMed has agreements. As RLS has communicated in the past,…
Read moreRLS Global continues to develop its Wound Care business area and sells off the dental care portfolio
RLS Global’s strategy is to ensure a strong market penetration for ChloraSolv together with regional/global partnerships. ChloraSolv is based on a unique buffered hypochlorite technology with documented clinical results within Advanced Wound Care. During 2020, RLS will initiate pre-clinical activities with the aim of broadening the product portfolio within new clinical areas. New clinical indications…
Read moreRLS Global AB (publ) Year-end Report, 2019
October 1st - December 31st • Net sales amounted to kSEK 54 (1,131) • The operating loss for the period was MSEK -8.9 (-5.9) • Earnings per share after dilution at SEK -0.15 (-0.10) • Cash flow from operating activities amounted to MSEK -5.7 (-5.0) • Cash and cash equivalents amounted to MSEK 41.8 (22.6)
Read moreAll patients enrolled for ChloraSolv01
RLS Global is pleased to announce that all patients are included in the study ChloraSolv 01, which has been performed on nine sites in Sweden. The inclusion criteria for the study are chronic wounds below the knee. The aim with the study is to obtain clinical data to regulatory extend the indication for use (diabetic…
Read moreRLS Global AB received its first order of ChloraSolv for clinical use
During the autumn of 2019, RLS Global focused on the Swedish market with the aim to get ChloraSolv established as a standard product in the regions. In parallel, RLS has worked in close collaboration with OneMed to penetrate the market in municipalities and regions there OneMed has supplier agreements. RLS Global also has ongoing dialogue with international players…
Read moreRLS GLOBAL AB (PUBL) Interim Report, January - September, 2019
July 1st - September 30th · Net sales amounted to SEK 0.2 million (1.0) · Earnings before interest and taxes (EBIT) amounted to SEK -6,1 million (-4,9) · Earnings per share before dilution at SEK -0,11 (-0,08) · Cash flow from operating activities amounted to SEK -7,4 million (-5,8) · Liquid assets at the end…
Read moreThe new Shareholder list at RLS Global AB
RLS Global AB completed a directed new share issue raising proceeds of SEK 50 million as of 25th of September. It is very encouraging that RLS has engaged national- and international institutions to establish a long-term foundation for the company, says Karin Fischer, CEO RLS Global. The new shareholder list can be found at RLS…
Read moreRLS Global completes a directed new share issue of 7,520,000 shares, raising proceeds of SEK 50 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR…
Read moreRLS Global announces intention of a directed new share issue of shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR…
Read moreRLS Global signs agreement with OneMed AB
OneMed is one of the Nordic Countries largest distributors within medical technology providing services, support systems and products to the healthcare sector. RLS Global AB has signed a cooperation agreement with OneMed AB who will act as a distributor for ChloraSolv to address the municipalities and county councils with whom they have agreements with for…
Read moreSettlement with Karin Bergqvist
Settlement with Karin Bergqvist
Read moreRLS Global AB (PUBL) - Annual Report 2018
RLS Global AB (PUBL) - Annual Report 2018
Read moreChloraSolv receives CE marking and is cleared for commercial launch in EU
Gothenburg, Sweden, April 10th, 2019 – RLS Global AB announces that ChloraSolv, its wound care product targeting diabetic foot ulcers, has successfully obtained a CE marking based on confirmation from Lloyd’s Register, acting as Notified Body, and is therefore cleared in 32 European countries for commercialization.
Read moreYear-end report 2018
Intensified work with ChloraSolv.
Read moreAbout RLS Global
RLS Global is a Swedish MedTech company based in Gothenburg, founded in 1996. Through our advanced and unique Buffered Hypochlorite based Technology Platform we focus on developing products based on Gentle methods for Minimally Invasive Treatment.
Visit us
RLS Global AB
Neongatan 5
SE 431 53 Mölndal
Sweden
Contacts
Customer Services & Orders:
+46 31 780 68 20
customer@rlsglobal.com
Office
+46 31 780 68 20
customer@rlsglobal.com
